New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 3, 2012
10:16 EDTINFY, EIX, QLGC, KNXA, HMA, CF, DVA, TEVA, OXY, JNS, ELX, RIMM, RDS.A, MYGN, SJM, CNK, RATEOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Bankrate (RATE) downgraded to Hold from Buy at Canaccord... Bankrate (RATE) downgraded to Sector Perform from Outperform at RBC Capital... CF Industries (CF) downgraded to Neutral from Overweight at Piper Jaffray... Cinemark (CNK) downgraded to Neutral from Overweight at JPMorgan... Emulex (ELX) downgraded to Sell from Neutral at Goldman... Health Management (HMA) downgraded to Sell from Fair Value at CRT Capital... J.M. Smucker (SJM) downgraded to Equal Weight from Overweight at Stephens... Janus Capital (JNS) downgraded to Sell from Neutral at Goldman... Kenexa (KNXA) downgraded to Market Perform from Outperform at JMP Securities... Myriad Genetics (MYGN) downgraded to Neutral from Buy at Mizuho... Occidental Petroleum (OXY) downgraded to Hold from Buy at Deutsche Bank... QLogic (QLGC) downgraded to Sell from Neutral at Goldman... Regal Entertainment (RGC) downgraded to Neutral from Overweight at JPMorgan... Royal Dutch Shell (RDS.A) downgraded to Hold from Buy at Deutsche Bank... Teva (TEVA) downgraded to Neutral from Buy at UBS... Edison International (EIX) downgraded to Market Perform from Outperform at Bernstein... Research in Motion (RIMM) downgraded to Sell from Hold at Canaccord... DreamWorks (DWA) downgraded to Sell from Hold at Stifel Nicolaus... Infosys (INFY) downgraded to Neutral from Outperform at Cowen.
News For A;TEVA;EIX;RIMM;DVA;INFY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
April 17, 2015
14:48 EDTTEVAMylan says tie-up with Teva 'without sound industrial logic or cultural fit'
14:31 EDTTEVAMylan jumps after reports of potential bid from Teva
Shares of Mylan (MYL) jumped in afternoon trading after The Wall Street Journal and Bloomberg separately reported that Teva (TEVA) is exploring a takeover offer for the company. Both reports, which each cited sources, said Teva is evaluating a bid internally, but that the company has not made any formal offer as of yet. WHAT'S NOTABLE: In a note to investors this morning, analysts at Cowen said the approval of a generic version of Teva's 20mg Copaxone should spur management to make a value-creating decision to acquire Mylan. The firm also believes in Teva's skill in protecting its Copaxone asset and said now is the time to pursue aggressive strategic actions. Cowen reiterated its Outperform rating and $100 price target on Teva shares. ANOTHER TO WATCH: On April 8, Mylan announced that it delivered to Perrigo's Chairman on April 6 a non-binding proposal to buy the company for $205 per share in a combination of cash and Mylan stock. RBC Capital analyst Randall Stanicky said earlier this week he believed Perrigo may be engaging other companies in talks after Mylan made its offer public. Stanicky sees no clear competing bidder for Perrigo, however, and used a $230 per share takeover while analyzing possible deals. PRICE ACTION: In afternoon trading, Mylan shares rose 5.6% to $70.58, Teva added 3.7% to $65.53 and Perrigo fell 2.5% to $193.99.
14:23 EDTTEVAMylan jumps after Dow Jones says Teva considering bid
Subscribe for More Information
14:21 EDTTEVATeva weighing potential bid for Mylan, Dow Jones says
Subscribe for More Information
12:56 EDTTEVAFederal Circuit upholds Mylan's patents on Perforomist inhalation solution
Mylan (MYL) announced the United States Court of Appeals for the Federal Circuit upheld the validity and infringement of all four patents asserted by Mylan Specialty, L.P. protecting its Perforomist Inhalation Solution. The Court summarily affirmed the previous decision by the district court against Teva (TEVA). Today's decision prevents Teva from receiving final approval of its ANDA from the FDA prior to expiration of U.S. Patent Nos. 6,667,344; 6,814,953; 7,348,362; and 7,462,645. Those patents cover Perforomist until they expire in June 2021.
08:12 EDTTEVATeva pullback a buying opportunity, says Leerink
Leerink views yesterday's pullback in shares of Teva after generic Copaxone was approved as a buying opportunity. The firm notes Teva remains confident in its $5 earnings per share floor. Leerink views the company's outlook as "bright" and keeps an Outperform rating on the name.
08:00 EDTTEVATeva patent loss should move management to acquire Mylan, says Cowen
Subscribe for More Information
April 16, 2015
16:02 EDTTEVAOptions Update; April 16, 2015
Subscribe for More Information
15:40 EDTTEVAGeneric Copaxone approval a bit early but expected, says BMO Capital
BMO Capital believes FDA approval for Sandoz (NVS) and Momenta's (MNTA) generic 20mg Copaxone came slightly earlier than the market expected, but the firm added that the generic threat has been well expected. The firm added that it appears Mylan’s (MYL) generic Copaxone hasn't been approved yet, leaving a "legitimate question" about why the FDA approved one generic and not the other. BMO thinks Teva's rate of conversion to the 40mg dose will help retain patients on the Copaxone franchise and it keeps an Outperform rating on Teva shares.
13:42 EDTTEVATeva shares defended at Evercore ISI
Subscribe for More Information
12:37 EDTTEVAMomenta confirms Glatopa approval, to receive $10M payment
Subscribe for More Information
12:35 EDTTEVASandoz receives FDA approval for Glatopa as generic competitor to Copaxone
Sandoz, a Novartis (NVS) company, announced the U.S. approval of Glatopa, the first generic version of Teva's (TEVA) Copaxone 20 mg/ml one-time-daily multiple sclerosis therapy. Glatopa, developed in collaboration with Momenta (MNTA) and produced entirely in the U.S., is indicated for the treatment of patients with relapsing forms of MS, including those who have experienced a first clinical episode and have magnetic resonance imaging features consistent with MS.
12:35 EDTTEVAFDA denies Teva attempt to block generic Copaxone
Subscribe for More Information
06:16 EDTTEVAFormer Teva CEO appointed to position of CEO at Ovid Therapeutics
Ovid Therapeutics, a privately held biopharmaceutical company focused on developing therapies for rare and orphan diseases of the brain, appointed Dr. Jeremy Levin as CEO. Levin has served as Chairman of Ovid since 2014 and will continue to serve in this role. Most recently, Levin served as CEO of Teva.
April 15, 2015
19:34 EDTTEVAVIVUS files patent infringement lawsuit against Teva
Subscribe for More Information
10:01 EDTDVADaVita sees taking $250M reserve for Vanier litigation
In a regulatory filing yesterday related to a bond offering, DaVita noted it has received subpoenas or other requests for documents from the federal government in connection with the Vainer private civil suit, the Swoben private civil suit, the 2011 U.S. Attorney Medicaid investigation, the 2015 U.S. Attorney Transportation Investigation and the JSA investigation. In each of the Vainer and Swoben private civil suits, a relator filed a complaint against the company in federal court under the qui tam provisions of the False Claims Act and pursued the claims independently after the government declined to intervene. With regard to the Vanier private civil suit, the parties are engaged in active litigation. The parties in that suit completed discovery in early 2014; however, in August 2014, the court granted relators’ motion for sanctions and reopened discovery on a limited basis. The court in Vainer is considering the plaintiffs’ request for further sanctions, which could result in a range of outcomes from no other sanctions to plaintiffs’ request to strike our answer. Certain of these sanctions could materially adversely impact the company's ability to defend the case, DaVita said. "While we cannot predict the ultimate outcome of this case, if the case is resolved in favor of the plaintiffs, its resolution could have a material adverse effect on our earnings and cash flows. We recently commenced settlement discussions with the plaintiffs in Vainer." The company said it expects to accrue an estimated loss contingency reserve of $250M related to this matter. "Negotiations are ongoing and we can make no assurances as to whether the Vainer suit will settle and, if it does settle, whether it will settle for an amount higher than the current reserve," DaVita added. With regard to the Swoben private civil suit, in July 2013, the court granted HCP’s motion and dismissed with prejudice all of the claims in the Third Amended Complaint, and in October 2013 the plaintiff filed an appeal of the dismissal, which is currently pending.
April 14, 2015
12:13 EDTDVADaVita announces $725.94M repurchase program
Subscribe for More Information
08:03 EDTTEVATeva, Eagle announce NDA for bendamustine HCI accepted for filing
Subscribe for More Information
April 13, 2015
16:18 EDTAeBay announces executive appointments ahead of PayPal separation
Subscribe for More Information
07:56 EDTTEVAMylan, Teva, Perrigo price targets raised at JPMorgan
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use